Herpes virus helicase-primase inhibitor, Amenamevir is available now! Amenamevir, also known as ASP2151, is a herpes virus helicase-primase inhibitor. Amenamevir was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Jul 3, 2017 and marketed as Amenalief
CL 316243 disodium salt(151126-84-0) is a potent and highly selective β3-adrenoceptor agonist (EC50 = 3 nM); > 10000-fold selective over β1 and β2 receptors. Increases brown adipose tissue thermogenesis and metabolic rate, and decreases blood insulin and glucose levels following oral administration in vivo.
评论
发表评论